Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 14;15(1):1143-1149.
doi: 10.1515/med-2020-0138. eCollection 2020.

A review of current progress in triple-negative breast cancer therapy

Meiying Shen  1 , Huawen Pan  2 , Yuxia Chen  1 , Yu Hang Xu  1 , Weixiong Yang  1 , Zhaojun Wu  3
Affiliations
Review

A review of current progress in triple-negative breast cancer therapy

Meiying Shen et al. Open Med (Wars). .

Abstract

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2-3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade.

Keywords: PARP inhibition; adjuvant therapy; immunotherapy; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no competing interests.

References

    1. Pareja F, Reis-Filho JS. Triple-negative breast cancers – a panoply of cancer types. Nat Rev Clin Oncol. 2018;15(6):347–8. 10.1038/s41571-018-0001-7. - DOI - PubMed
    2. Pareja F, Reis-Filho JS. Triple-negative breast cancers – a panoply of cancer types. Nat Rev Clin Oncol. 2018;15(6):347–8. doi: 10.1038/s41571-018-0001-7. - DOI - PubMed
    1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. 10.1172/JCI45014. - DOI - PMC - PubMed
    2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. 10.1056/NEJMra1001389. - DOI - PubMed
    2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. doi: 10.1056/NEJMra1001389. - DOI - PubMed
    1. Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA deficiency in breast cancer: what are the clinical evidences and the next perspectives?. Cancers (Basel). 2018;10(12):506. 10.3390/cancers10120506, Published 2018 Dec 11. - DOI - PMC - PubMed
    2. Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA deficiency in breast cancer: what are the clinical evidences and the next perspectives? Cancers (Basel) 2018;10(12):506. doi: 10.3390/cancers10120506. Published 2018 Dec 11. - DOI - PMC - PubMed
    1. Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–27. 10.18632/oncotarget.12158. - DOI - PMC - PubMed
    2. Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W. et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–27. doi: 10.18632/oncotarget.12158. - DOI - PMC - PubMed

LinkOut - more resources